Regeneron Pharmaceuticals, Inc. (REGN)
NASDAQ: REGN · Real-Time Price · USD
640.14
+6.00 (0.95%)
At close: Mar 26, 2025, 4:00 PM
634.00
-6.14 (-0.96%)
After-hours: Mar 26, 2025, 6:00 PM EST
Regeneron Pharmaceuticals Revenue
In the year 2024, Regeneron Pharmaceuticals had annual revenue of $14.20B with 8.27% growth. Regeneron Pharmaceuticals had revenue of $3.79B in the quarter ending December 31, 2024, with 10.33% growth.
Revenue (ttm)
$14.20B
Revenue Growth
+8.27%
P/S Ratio
4.86
Revenue / Employee
$940,156
Employees
15,106
Market Cap
68.51B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 14.20B | 1.08B | 8.27% |
| Dec 31, 2023 | 13.12B | 944.30M | 7.76% |
| Dec 31, 2022 | 12.17B | -3.90B | -24.26% |
| Dec 31, 2021 | 16.07B | 7.57B | 89.14% |
| Dec 31, 2020 | 8.50B | 1.94B | 29.58% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
REGN News
- 1 day ago - Regeneron to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2025 - GlobeNewsWire
- 2 days ago - Lawsuit Notice: Investors who hold Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) shares should contact the Shareholders Foundation - GlobeNewsWire
- 12 days ago - Regeneron Pharmaceuticals Has Lost Its Way, But Can It Find It Again? - Seeking Alpha
- 15 days ago - Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Research on Classifying Celestial Objects, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem - PRNewsWire
- 15 days ago - Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Scientific Research on Classifying Objects in Space, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem - GlobeNewsWire
- 15 days ago - Regeneron Pharmaceuticals, Inc. (REGN) Leerink Partners 2025 Global Healthcare Conference Call Transcript - Seeking Alpha
- 18 days ago - Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD - GlobeNewsWire
- 18 days ago - Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD - GlobeNewsWire